PT - JOURNAL ARTICLE AU - Rajesh Didhiya AU - Tara Nath Pokhrel AU - Sudha Devkota AU - Purusotam Raj Shedain AU - Mukunda Sharma AU - Madan Kumar Shrestha AU - Deepak Gyenwali AU - Muhammad Imran AU - Zakir Kadirov AU - Bhawani Prasad Dahal AU - Amrit Bikram Rai AU - KC Prawachan Kumar AU - Sabir Ojha AU - Khem Narayan Pokhrel TI - Community Led Testing among People Who Inject Drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal AID - 10.1101/2021.02.20.21251607 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.20.21251607 4099 - http://medrxiv.org/content/early/2021/02/23/2021.02.20.21251607.short 4100 - http://medrxiv.org/content/early/2021/02/23/2021.02.20.21251607.full AB - Background People Who Inject Drugs (PWIDs) have sub-optimal HIV and HCV testing as the available testing services are inadequate in low and middle-income countries. We examined a model of Community-Led Testing (CLT) in Nepal, exploring the feasibility of HIV and HCV testing by trained lay service providers who had similar backgrounds to those of PWIDs. We also assessed the prevalence of HIV and HCV within this study population and the associated risk factors among PWIDs.Methods A mix-method cross-sectional study was conducted among 1029 PWIDs in five major districts of Nepal from July 2019 to February 2020. Trained PWID peers performed the screening for HIV and HCV using Rapid Diagnostic Test (RDT) kits. Acceptability and feasibility of the testing was assessed. The participants’ sociodemographic characteristics and injecting and non-injecting risk characteristics were determined. The association of risk and prevention characteristics with testing results were assessed using multiple logistic regression.Results PWIDs shared that the test providers were friendly and competent in counseling and testing. Of total PWIDs (n=1,029), 20.6% were HCV-positive and 0.2% were HIV-positive. HCV positivity was associated with needle sharing (AOR: 1.83, 95% CI: 1.27,2.64; p=0.001) and reuse of syringe/needle (AOR: 2.26; 95% CI: 1.34, 3.79; p=0.002). In addition, PWIDs were more likely to be HCV-positive who started opioid substitution therapy (OST) (AOR: 1.88, 95% CI: 1.26, 2.80, p=0.002) and attended the rehabilitation center (AOR: 1.66, 95% CI: 1.10, 2.53, p=0.017).Conclusions This CLT model was found to be a novel approach of testing of HIV and HCV which was acceptable to PWIDs in Nepal and showed the high prevalence of HCV and its association with injecting-related risk behaviors and being users of OST and rehabilitation. The findings highlight the need of community-led testing in hotspots, OST settings, and rehabilitation centers to screen new HIV and HCV infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no funding for this study itself.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:"Ethical approval was obtained from the ethical review board of the Nepal Health Research Council (NHRC) [Reg No. 552/2019]."All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be available upon request